ARQT
Arcutis Biotherapeutics Inc
24.20$
+1.0%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
Arcutis Biotherapeutics Inc (ARQT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 130 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 3.0 | 2.8 | 5.2 | 38 | 14 | 50 | 31 | 45 | 71 | 66 | 82 | 99 | 130 | 105 | 130 | 464 | |
| – | – | – | – | – | – | – | 0.1 | 0.1 | 0.1 | – | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.5 | 0.8 | 0.8 | 1.2 | 2.2 | 3.3 | 3.5 | 5.5 | 6.9 | 8.8 | 7.5 | 8.7 | 12 | 9.8 | 11 | 41 | |
| – | – | – | – | – | – | – | -0.1 | -0.1 | -0.1 | – | -0.2 | -0.2 | -0.2 | -0.2 | -0.2 | -0.2 | -0.2 | 0.5 | 2.5 | 2.0 | 4.4 | 37 | 11 | 46 | 27 | 39 | 64 | 57 | 74 | 91 | 118 | 96 | 119 | 423 | |
| 2.8 | 2.8 | 7.1 | 5.3 | 6.2 | 7.2 | 12 | 11 | 25 | 30 | 33 | 27 | 22 | 31 | 41 | 53 | 41 | 38 | 70 | 34 | 35 | 25 | 26 | 24 | 23 | 19 | 20 | 14 | 18 | 19 | 20 | 20 | 31 | 20 | 91 | |
| 0.3 | 0.3 | 0.6 | 0.6 | 0.7 | 1.3 | 2.3 | 2.2 | 3.5 | 5.6 | 5.6 | 6.7 | 14 | 11 | 16 | 19 | 22 | 28 | 35 | 50 | 5.8 | 46 | 48 | 136 | 55 | 58 | 59 | 58 | 64 | 69 | 62 | 79 | 74 | 82 | 298 | |
| 3.0 | 3.0 | 7.6 | 6.0 | 7.0 | 8.5 | 15 | 13 | 29 | 36 | 38 | 34 | 36 | 42 | 57 | 71 | 62 | 66 | 105 | 71 | 78 | 71 | 74 | 72 | 78 | 77 | 78 | 72 | 82 | 89 | 82 | 99 | 105 | 102 | 389 | |
| -3.0 | -3.0 | -7.7 | -6.0 | -7.0 | -8.5 | -15 | -13 | -29 | -36 | -38 | -34 | -36 | -42 | -57 | -71 | -63 | -66 | -105 | -68 | -76 | -67 | -37 | -61 | -32 | -50 | -39 | -7.6 | -25 | -15 | 8.5 | 18 | -9.1 | 16 | 34 | |
| – | – | 0.0 | – | 0.5 | 0.5 | 0.5 | – | – | – | – | – | – | – | – | – | 1.8 | 2.0 | 4.9 | 6.9 | 7.0 | 7.3 | 7.6 | 7.8 | 7.5 | 7.5 | 6.7 | 5.6 | 3.0 | 3.0 | 3.1 | 3.0 | 4.4 | 3.4 | 14 | |
| -3.0 | -3.0 | -7.7 | -5.6 | -6.7 | -8.3 | -14 | -13 | -28 | -35 | -38 | -34 | -36 | -42 | -57 | -71 | -64 | -67 | -108 | -72 | -80 | -71 | -42 | -66 | -35 | -52 | -42 | -10 | -25 | -16 | 7.5 | 18 | -11 | 15 | 29 | |
| 0.1 | 0.1 | 0.0 | -6.0 | – | – | – | – | – | 0.0 | – | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | 1.7 | 1.6 | 3.0 | 3.6 | -0.4 | 10 | 3.0 | 0.0 | 0.3 | 0.3 | – | 0.3 | 0.3 | 0.3 | 0.1 | 0.5 | 0.1 | 0.1 | 0.8 | |
| -3.0 | -3.0 | -7.7 | -5.6 | -6.7 | -8.3 | -14 | -13 | -28 | -35 | -38 | -34 | -36 | -42 | -57 | -71 | -64 | -67 | -108 | -72 | -80 | -71 | -45 | -66 | -35 | -52 | -42 | -11 | -25 | -16 | 7.4 | 17 | -11 | 15 | 29 | |
| 0.1 | 0.1 | 0.0 | -6.0 | -6.9 | -8.5 | -15 | -13 | -28 | -35 | -38 | -34 | -36 | -42 | -57 | -71 | -62 | -65 | -103 | -65 | -73 | -63 | -34 | -58 | -27 | -44 | -33 | -4.5 | -19 | -12 | 11 | 22 | -6.3 | 17 | 44 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.